Clifford Csizmar

Heme/Onc fellow (@MayoHemeOnc) & clinician investigator (@MayoCITProgram) at Mayo Clinic. MD/PhD from University of Minnesota (@umnmstp). Opinions my own.

[Mrinal Patnaik @MrinalPatnaik]

Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia - PubMed ⁦@MDAndersonNews⁩ ⁦@MayoCancerCare⁩ ⁦@BloodPortfolio⁩ GMB ⁦@sanamloghavi⁩ ⁦@doctorpemm⁩ ⁦@ccsizmar⁩ #CMML #RAS https://t.co/1EXoC0aoPA

[Clifford Csizmar @ccsizmar]

When it comes to TET2 mutations in CMML, more are better! Multiple TET2 mt offset the negative impacts of ASXL1 and RAS mutations in myelodysplastic and myeloproliferative CMML, respectively. @MrinalPatnaik https://t.co/oTsBJxJLjw

[Clifford Csizmar @ccsizmar]

A bit late, but our review of Antibody-Based and Other Novel Agents in Adult B-ALL is out! Many thanks to Drs. Saliba and Litzow @MRLitzow for their expertise! https://t.co/uatEAZK7NT

[Duke Kidney @DukeKidney]

Congratulations to Dr. Tomasi @AleTomasiMD on being appointed as the chief nephrology fellow for the academic year 2025-2026.

[Mayo Clinic Hematology-Oncology Fellowship @MayoHemeOnc]

It’s been an incredible few days at #ASH24, here are some of our second year fellows representing their work! @SavannahLiddel1 @ccsizmar @SyedaMinaMD

[Mayo Clinic Internal Medicine Residency Rochester @MayoMN_IMRES]

Happy #ManuscriptMonday featuring a publication by PGY2 Dr. Tessier!! @CaThompsonMD ✨📚

[Aref Al-Kali @AlkaliDr]

A new hope for our patients with MLL/KMT2A positive rr#Acute_leukemia ❤️ 💊

[Clifford Csizmar @ccsizmar]

Out now! Our institutional series of DEK::NUP214 rearranged AML showing favorable outcomes post-HCT. FLT3 inhibitors may help get there. Grateful to @AlkaliDr and Dr. Scott Kaufmann for the mentorship! https://t.co/e54ZjnmcTn

[Mrinal Patnaik @MrinalPatnaik]

Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matche… https://t.co/RwcIvX64IE @GMontalbanBravo Doug Tremblay @ccsizmar @md_padron #CMML #Venetoclax

[Clifford Csizmar @ccsizmar]

Out now! Our work showing that ASXL1/TET2 co-mutation status enhances risk-stratification in CMML independent of VAF. Grateful to @MrinalPatnaik for the mentorship and to @GMontalbanBravo and @md_padron for the collaboration! https://t.co/s6SoySAzol

[Mrinal Patnaik @MrinalPatnaik]

Are you interested in understanding how #RAS mutations could be targeted in #CMML please read our review in @Haematologica by @LudovicaMarando and @ccsizmar #KRAS #NRAS #SHP2 #PLK1 #WEE1 @MayoCancerCare

[Mrinal Patnaik @MrinalPatnaik]

https://t.co/KX9XQACXjp #CMML Molecular pathobiology and therapeutic vulnerabilities @LudovicaMarando @ccsizmar #ASXL1 #RAS @MayoCancerCare @Haematologica

[Mayo Clinic Hematology-Oncology Fellowship @MayoHemeOnc]

A few more highlights from Mayo fellows at #ASCO24! @ASridharMD @Aditisinghlove

[Mayo Clinic Hematology-Oncology Fellowship @MayoHemeOnc]

Our fellows presenting their projects at #ASCO24! @AHazimMD @RichGodby

[Joshua Pritchett, MD @JPritchettMD]

Hard to find the words to convey the significance of this. What an immense privilege and opportunity to share our journey of design, implementation, and impact of this program through the @nejmcatalyst platform. Thanks to @MayoCancerCare @MayoClinic @MayoMN_IMRES @MayoHemeOnc @MayoKernScholar. Thanks most of all to our patients. This work is for you. Free link to full article will be provided in the comments.

[Mayo Clinic Internal Medicine Residency Rochester @MayoMN_IMRES]

We are SO EXCITED to welcome our incoming PGY1 categorical and prelim residents to Mayo Clinic!!!

Congratulations and we can’t wait to see you in June!!! 🥳🤩😍🎉

@CaThompsonMD @AleTomasiMD @IMChrisKerryMD @BenStultz @BonnesSara @CStephenson_MD @GallodeMoraesMD @Khanna_S

[CFI-UMN @CFI_UMN]

Congratulations to our former students and future collaborators!! Your hard work and dedication have truly paid off. Wishing you continued success in all your future endeavors! @UMNMSTP

[Mayo Clinic Hematology-Oncology Fellowship @MayoHemeOnc]

Excellent grand rounds given by our very own Dr Pritchett whose hard work is bringing health care closer to the patients 👏🏻
@JPritchettMD

[Mayo Clinic Hematology-Oncology Fellowship @MayoHemeOnc]

Phenomenal lecture by Dr. Al-Kali on relapsed refractory AML this morning. A very complex topic condensed into understandable and practical treatment considerations. Thank you @AlkaliDr #MedEd

[Mayo Clinic Hematology-Oncology Fellowship @MayoHemeOnc]

Congratulations Dr. Zanwar on many recent accomplishments!! Dr. Zanwar was recently awarded the Mayo Brothers Distinguished Fellowship Award in addition to obtaining a Hematology Small Grant and Merit Award. We are amazed by all you do! @ZanwarSaurabh